Skip to main content
. 2020 May 31;12(6):1434. doi: 10.3390/cancers12061434

Figure 1.

Figure 1

Gint4.T-mediated delivery of STAT3 siRNA in primary GSCs. (a–c) Primary GSCs (PDGFRβ+) were treated with 400 nmol/L Gint4.T, Gint4.T-STAT3, control aptamer (CtrlApt), or control chimera (CtrlApt-STAT3) as indicated. After 72 h, the STAT3 protein (left panels) or mRNA (right panels) levels were analysed by immunoblotting or RT-qPCR, respectively. Anti-tubulin antibody was used as an immunoblot loading control. Values below the blots indicate quantization relative to the untreated (“−”) sample, labelled with an asterisk normalized on the loading control signals. Error bars depict the mean ± SD on two experimental replicates. Statistics were calculated using one-way ANOVA: *, p < 0.05; ***, p < 0.001, (Gint4.T-STAT3 versus control chimera). Whole blots of Figure 1 are shown in Figure S6.